A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer´s Disease

Trial Profile

A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer´s Disease

Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Baxalta
  • Most Recent Events

    • 20 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 31 Jan 2013 New trial record
    • 10 Dec 2012 Status of the extension study changed from not yet recruiting to recruiting, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top